SIGA Technologies is a public, commercial-stage pharmaceutical company that focuses on providing solutions for unmet needs in health security. They are dedicated to developing and delivering medical countermeasures for biological, chemical, radiological, and nuclear attacks. SIGA's products include TPOXX (Tecovirimat-SIGA), which played a key role in the global response to the recent mpox (monkeypox) outbreak.

TPOXX is approved by the U. S. FDA and Health Canada for the treatment of Smallpox and by the EMA and MHRA for the treatment of monkeypox, cowpox, smallpox, and complications from the vaccinia virus.

With an experienced team of scientists and business leaders, SIGA is focused on attractive product and market expansion opportunities. They have a rich history of successful partnerships and have been named 27th on the Forbes List of Best Small Cap Companies. For inquiries, reach out to monkeypox@siga.

com